Sygnamap Inc.
San Antonio, TX
- UEI
- FH41QG5NZ2Y6
- CAGE
- 8H8G6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 7733 Louis Pasteur Dr #301, San Antonio, TX 78229, USA
- Website
- sygnamap.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Sygnamap Inc. is a minority-owned, for-profit corporate entity located in San Antonio, Texas, registered in SAM.gov and specializing in computational platforms for advanced medical research and drug development technologies. The company focuses on developing innovative computational approaches that leverage spatial metabolomics, mass spectrometry imaging, and artificial intelligence/machine learning techniques to analyze complex biological data. Sygnamap's core technological expertise centers on creating computational platforms that can quantify and normalize molecular data to support precision medicine and drug discovery efforts.
Through its federal grant awards, Sygnamap Inc. has consistently received funding from prestigious federal agencies including the National Institute of Standards and Technology (NIST), National Institute of General Medical Sciences, National Science Foundation, and National Institute of Diabetes and Digestive and Kidney Diseases. The company's grant-funded projects predominantly focus on developing advanced computational platforms for analyzing spatial metabolomics data, with specific emphasis on disease pathway identification, particularly in kidney disease, diabetic nephropathy, and broader medical research domains. Notable projects include developing MSI-DEEPPATH, a computational platform for quantifying spatially distinct metabolite abundancies, creating technologies to infer causative disease pathways, and designing innovative point-of-care devices for measuring chiral metabolites. These projects typically involve developing computational models, establishing calibration standards, and creating technologies that can convert semi-quantitative mass spectrometry data into rigorous, quantitative results to support biotech and pharmaceutical research and development efforts.
Quick answers
Is Sygnamap Inc. registered in SAM.gov?
Yes. Sygnamap Inc.'s SAM.gov registration is active through May 26, 2027.
What is Sygnamap Inc.'s most recent federal award?
Sygnamap Inc.'s most recent federal grant award is Traceable reference standards is becoming an indispensable tool for pharmaceutical companies to identify therapeutic… (70NANB24H198), from National Institute of Standards and Technology, on October 1, 2024.
On GovTribe
See Sygnamap Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors